JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

Search

Eli Lilly and Co.

Gesloten

SectorGezondheidszorg

696.49 -1.99

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

694.22

Max

712.89

Belangrijke statistieken

By Trading Economics

Inkomsten

2.9B

5.7B

Verkoop

2.8B

16B

K/W

Sectorgemiddelde

45.864

35.473

EPS

6.31

Dividendrendement

0.8

Winstmarge

36.384

Werknemers

47,000

EBITDA

3.3B

7.5B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+31.86% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.80%

2.38%

Volgende Winsten

30 okt 2025

Volgende dividenddatum

10 sep 2025

Volgende Ex Dividend datum

14 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-62B

629B

Vorige openingsprijs

698.48

Vorige sluitingsprijs

696.49

Nieuwssentiment

By Acuity

38%

62%

136 / 372 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Eli Lilly and Co. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 aug 2025, 15:59 UTC

Belangrijke Marktbewegers

Immuneering Shares Climb On Supply Agreement with Eli Lilly

7 aug 2025, 11:36 UTC

Winsten

Eli Lilly Lifts Full-Year Outlook After Revenue Surges on Zepbound, Mounjaro Demand

12 aug 2025, 22:15 UTC

Acquisities, Fusies, Overnames

Lilly CEO Buys $1 Million of Stock After Share-Price Drop on Obesity Drug Data -- Barrons.com

8 aug 2025, 19:34 UTC

Marktinformatie

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8 aug 2025, 05:32 UTC

Marktinformatie

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 aug 2025, 16:20 UTC

Winsten

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 4th Update

7 aug 2025, 14:18 UTC

Marktinformatie
Winsten

Eli Lilly's Orforglipron Results Weigh on Stock -- Market Talk

7 aug 2025, 13:54 UTC

Winsten

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 3rd Update

7 aug 2025, 12:12 UTC

Winsten

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 2nd Update

7 aug 2025, 11:58 UTC

Winsten

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- Update

7 aug 2025, 11:32 UTC

Winsten

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 aug 2025, 11:03 UTC

Winsten

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 aug 2025, 10:49 UTC

Winsten

Eli Lilly 2Q Gross Margin 84.3% >LLY

7 aug 2025, 10:48 UTC

Winsten

Eli Lilly 2Q Volume Rose 42%, Realized Prices Fell 6% >LLY

7 aug 2025, 10:47 UTC

Winsten

Eli Lilly Raises 2025 Adjusted Performance Margin View to 43%-44.5% From 41.5%-43.5% >LLY

7 aug 2025, 10:46 UTC

Winsten

Eli Lilly Had Seen 2025 Adjusted EPS $20.78-$22.28 >LLY

7 aug 2025, 10:46 UTC

Winsten

Eli Lilly Had Seen 2025 Revenue $58B-$61B >LLY

7 aug 2025, 10:46 UTC

Winsten

Eli Lilly Raises 2025 View To Rev $60B-$62B >LLY

7 aug 2025, 10:45 UTC

Winsten

Eli Lilly 2Q Net $5.66B >LLY

7 aug 2025, 10:45 UTC

Winsten

Eli Lilly 2Q Rev $15.56B >LLY

7 aug 2025, 10:45 UTC

Winsten

Eli Lilly Sees FY Adj EPS $21.75-Adj EPS $23.00 >LLY

7 aug 2025, 10:41 UTC

Winsten

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6 aug 2025, 20:34 UTC

Winsten

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6 aug 2025, 08:45 UTC

Winsten

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

30 jul 2025, 10:38 UTC

Marktinformatie

Novo Nordisk Could Struggle to Regain Investors' Trust -- Market Talk

29 jul 2025, 17:05 UTC

Winsten

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- 3rd Update

29 jul 2025, 16:55 UTC

Winsten

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

29 jul 2025, 13:35 UTC

Winsten

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- Update

29 jul 2025, 11:39 UTC

Winsten

Novo Nordisk Stock Tumbles 20% After Ozempic Maker's Shock Cut to U.S. Outlook -- Barrons.com

25 jul 2025, 12:49 UTC

Acquisities, Fusies, Overnames

Lilly Completes Acquisition Of Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

Peer Vergelijking

Prijswijziging

Eli Lilly and Co. Prognose

Koersdoel

By TipRanks

31.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 938.39 USD  31.86%

Hoogste 1,190 USD

Laagste 700 USD

Gebaseerd op 22 Wall Street-analisten die 12-maands prijsdoelen bieden voor Eli Lilly and Co. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

22 ratings

17

Buy

5

Hold

0

Sell

Technische score

By Trading Central

N/A / 884.54Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

136 / 372 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.